BerGenBio ASA - Ex. reverse share split and change of ISIN today
Issuer name: BerGenBio ASA
Ex. date: 30 May 2024
Type of corporate action: Reverse share split
Reverse split ratio: One hundred (100) old shares give one (1) new share.
New par value per share: NOK 10
New ISIN: NO 001 3251173
New number of shares outstanding: 39,087,116
For further information, please contact:
Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
This information is published in accordance with the requirements of the Continuing Obligations pursuant to Oslo Rule Book II.